DNLI 241220 30.00P (DNLI241220P30000) Stock Options, News & Quotes

US OptionsDetailed Quotes

DNLI241220P30000

Watchlist

4.80
0.000.00%

15min DelayClose Nov 18 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
Yahoo FinanceNov 15 08:29 ET
Denali Therapeutics Insider Sold Shares Worth $1,932,665, According to a Recent SEC Filing
MT NewswiresNov 13 19:06 ET
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $34
Moomoo NewsNov 12 22:32 ET · Ratings
B.Riley Financial Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $33
Moomoo NewsNov 8 09:38 ET · Ratings
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
Zacks Nov 8 09:35 ET
Denali Therapeutics (DNLI) Receives a Hold From Stifel Nicolaus
TipRanksNov 7 09:39 ET · Ratings

Comments

Meltyy

May 16 01:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

Kevin Travers

Feb 27 10:02

Columns Biotechnology Stocks Climbing on Earnings and Test Results: What to Watch

$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...

Moomoo AI

Feb 7 06:59

Denali Therapeutics' continuous stock price drop questions the initial investment decision. The company's struggle to increase revenue while unprofitable worries investors. Despite a recent 3.9% rise, the company's disappointing performance over the past years resulted in a yearly 3% total loss for shareholders over five years.

Denali Therapeutics (NASDAQ:DNLI) Shareholders Are up 3.9% This Past Week, but Still in the Red Over the Last Three Years

MangoXoXo

Jan 30 18:16

$Denali Therapeutics (DNLI.US)$ 👀

Meltyy

Jan 24 03:25

Ph2 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...